GriggsRC, BatshawM, DunkleM. 2009. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab, 96:20-26.
3.
HornEJ, TerrySF. 2012. Precision medicine: generating real-world evidence for companion diagnostics. Genet Test Mol Biomark, 16:75-76.
4.
KhouryMJ, CoatesRJ, EvansJP. 2010. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet Med, 12:680-683.
5.
LeskoLJ, AtkinsonAJJr. 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol, 41:347-366.
6.
ManolioTA, WeisBK, CowieCCet al.2012. New models for large prospective studies: is there a better way?Am J Epidemiol, 175:859-866.
7.
MichaelsM, WeissES, GuidryJAet al.2012. The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual. J Cancer Educ, 27:67-74.
8.
NormanTC, BountraC, EdwardsAM, YamamotoKR, FriendSH. 2011. Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci Translat Med, 3:88mr1.
9.
O'DohertyKC, BurgessMM, EdwardsK. 2011. From consent to institutions: designing adaptive governance for genomic biobanks. Soc Sci Med, 73:367-374.
10.
RitchieMD, DennyJC, CrawfordDCet al.2010. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Human Genet, 86:560-772.
SurhLC, LeskoLJ, HobbsSet al.2009. Fit-for-purpose pharmacogenomic biomarkers in drug developme nt: a project team case study with 'what-ifs'Pharmacogenomics, 10:137-147.
13.
TerrySF, TerryPF. 2011. Power to the people: participant ownership of clinical trial data. Sci Transl Med, 3:69cm3.
